Patents by Inventor Tariq Ghayur

Tariq Ghayur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-1 Binding Proteins
    Publication number: 20230112863
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 29, 2022
    Publication date: April 13, 2023
    Inventors: Chengbin WU, Dominic J. AMBROSI, Chung-ming HSIEH, Tariq GHAYUR
  • METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS
    Publication number: 20200222413
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-XL.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 16, 2020
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • IL-1 Binding Proteins
    Publication number: 20190389945
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Application
    Filed: February 1, 2019
    Publication date: December 26, 2019
    Inventors: Chengbin WU, Dominic J. AMBROSI, Chung-ming HSIEH, Tariq GHAYUR
  • NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOF
    Publication number: 20190233510
    Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
    Type: Application
    Filed: August 6, 2018
    Publication date: August 1, 2019
    Inventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
  • METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS
    Publication number: 20180369250
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-XL.
    Type: Application
    Filed: December 12, 2017
    Publication date: December 27, 2018
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS
    Publication number: 20180298093
    Abstract: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.
    Type: Application
    Filed: March 5, 2018
    Publication date: October 18, 2018
    Inventors: Boris Labkovsky, Tariq Ghayur, Georgeen Gaza-Bulseco, Pratibha Mishra, Subramanya Hegde, Sudha Krishnan
  • Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof
    Patent number: 10040852
    Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: August 7, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
  • IgM- or IgE-Modified Binding Proteins and Uses Thereof
    Publication number: 20180194861
    Abstract: Engineered binding proteins comprising a modified constant region, such as an IgG constant region modified to contain a CH2 domain from an IgM, a CH2 domain from an IgE, or a variant thereof, are disclosed. The binding proteins can be multispecific, including bi-, tri-, and tetra-specific constructs. Also disclosed are uses of the binding proteins in the diagnosis, prevention, and/or treatment of disease.
    Type: Application
    Filed: July 8, 2016
    Publication date: July 12, 2018
    Inventors: Feng Dong, Jijie Gu, Tariq Ghayur
  • Methods of treatment using selective Bcl-2 inhibitors
    Patent number: 9872861
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-XL.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 23, 2018
    Assignee: AbbVie Inc.
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • Monovalent binding proteins
    Patent number: 9856319
    Abstract: Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: January 2, 2018
    Assignee: ABBVIE INC.
    Inventors: Tariq Ghayur, Jijie Gu
  • Antibodies against platelet-derived growth factor (PDGF)
    Patent number: 9840554
    Abstract: Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: December 12, 2017
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Diana Bowley, Lucia Eaton, Feng Dong, Lorenzo Benatuil, Tariq Ghayur, Ravi Chari, Matthew Rieser, Anca Clabbers
  • Dual Variable Domain Immunoglobulin and Uses Thereof
    Publication number: 20170313786
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
    Type: Application
    Filed: February 8, 2017
    Publication date: November 2, 2017
    Inventors: Chengbin WU, Tariq Ghayur, Richard W. DIXON, Jochen G. SALFELD
  • GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS
    Publication number: 20170306010
    Abstract: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 26, 2017
    Inventors: Boris Labkovsky, Tariq Ghayur, Georgeen Gaza-Bulseco, Pratibha Mishra, Subramanya Hegde, Sudha Krishnan
  • METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS
    Publication number: 20170232000
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 17, 2017
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • Dual Variable Domain Immunoglobulins and Uses Thereof
    Publication number: 20170226200
    Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.
    Type: Application
    Filed: September 20, 2016
    Publication date: August 10, 2017
    Inventors: Tariq GHAYUR, Junjian Liu, Peter C. Isakson
  • DUAL SPECIFIC BINDING PROTEINS HAVING A RECEPTOR SEQUENCE
    Publication number: 20170096470
    Abstract: Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: September 15, 2016
    Publication date: April 6, 2017
    Inventors: Tariq Ghayur, Philip Bardwell
  • IL-1 BINDING PROTEINS
    Publication number: 20170058027
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Application
    Filed: May 16, 2016
    Publication date: March 2, 2017
    Applicant: AbbVie Inc.
    Inventors: Chengbin WU, Dominic J. AMBROSI, Chung-ming HSIEH, Tariq GHAYUR
  • Glycoengineered binding protein compositions
    Patent number: 9550826
    Abstract: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 24, 2017
    Assignee: AbbVie Inc.
    Inventors: Boris Labkovsky, Tariq Ghayur, Georgeen Gaza-Bulseco, Pratibha Mishra, Subramanya Hegde, Sudha Krishnan
  • BINDING PROTEINS AGAINST VEGF, PDGF, AND/OR THEIR RECEPTORS
    Publication number: 20170015742
    Abstract: Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.
    Type: Application
    Filed: June 15, 2016
    Publication date: January 19, 2017
    Inventors: Jijie GU, Diana BOWLEY, Lucia EATON, Feng DONG, Lorenzo BENATUIL, Tariq GHAYUR, Ravi CHARI, Matthew RIESER, Anca CLABBERS
  • Dual variable domain immunoglobulins and uses thereof
    Patent number: 9493560
    Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Junjian Liu, Peter C. Isakson